Wealth Enhancement Advisory Services LLC Buys Shares of 69,207 Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Wealth Enhancement Advisory Services LLC bought a new stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 69,207 shares of the biopharmaceutical company’s stock, valued at approximately $32,000.

Several other institutional investors have also added to or reduced their stakes in LXRX. Arizona State Retirement System boosted its stake in Lexicon Pharmaceuticals by 34.4% during the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 16,136 shares during the last quarter. Swiss National Bank boosted its stake in shares of Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Swiss National Bank now owns 426,600 shares of the biopharmaceutical company’s stock worth $315,000 after buying an additional 109,100 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Lexicon Pharmaceuticals by 60.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 24,615 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth $66,000. Finally, Wellington Management Group LLP boosted its stake in shares of Lexicon Pharmaceuticals by 2.1% in the 4th quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company’s stock worth $552,000 after buying an additional 15,249 shares during the last quarter. 74.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wall Street Zen assumed coverage on Lexicon Pharmaceuticals in a research note on Monday, April 21st. They issued a “sell” rating on the stock. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Tuesday, June 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $3.67.

Lexicon Pharmaceuticals Price Performance

NASDAQ LXRX opened at $1.08 on Friday. The company has a market capitalization of $390.41 million, a PE ratio of -2.12 and a beta of 1.13. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.22. The business’s fifty day moving average is $0.74 and its 200 day moving average is $0.67. Lexicon Pharmaceuticals, Inc. has a fifty-two week low of $0.28 and a fifty-two week high of $2.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.26 million. Lexicon Pharmaceuticals had a negative return on equity of 103.16% and a negative net margin of 568.04%. Sell-side analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.